Compare BMHL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | NYXH |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | Belgium |
| Employees | 9 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 161.9M |
| IPO Year | N/A | 2021 |
| Metric | BMHL | NYXH |
|---|---|---|
| Price | $5.91 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 3.5K | ★ 217.1K |
| Earning Date | 06-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $1.26 |
| 52 Week High | $6.35 | $8.59 |
| Indicator | BMHL | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 38.59 |
| Support Level | $5.58 | $1.26 |
| Resistance Level | $6.35 | $1.70 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 82.53 | 30.27 |
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.